Molecular pathological classification of colorectal cancer

Virchows Archiv

Volumn 469, Issue 2, 2016, Pages 125-134

  Müller, Mike F ^a   Ibrahim, Ashraf E K ^b,c   Arends, Mark J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c BEDFORD HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

Cancer; Chromosomal instability; Colorectal; Consensus molecular subtypes; Defective mismatch repair; Hypermutant; Microsatellite instability; Mutation; Polymerase epsilon; Serrated pathway; Somatic copy number alterations; The Cancer Genome Atlas; Ultramutant

Indexed keywords

APC PROTEIN; FRAGILE HISTIDINE TRIAD PROTEIN; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; SMAD3 PROTEIN; SMAD4 PROTEIN; RAS PROTEIN;

CANCER CLASSIFICATION; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; COLORECTAL CANCER; GENE EXPRESSION PROFILING; GENETIC PARAMETERS; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; MICROSATELLITE INSTABILITY; MICROSATELLITE STABLE; MISMATCH REPAIR; PRIORITY JOURNAL; RECTUM ADENOMA; REVIEW; WNT SIGNALING PATHWAY; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MOLECULAR PATHOLOGY; MUTATION; PATHOLOGY;

COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROSATELLITE INSTABILITY; MUTATION; PATHOLOGY, MOLECULAR; RAS PROTEINS;

EID: 84975257508     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-016-1956-3     Document Type: Review

References (55)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D, Forman D, Bray F (2013) GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer. http://globocan.iarc.fr. Accessed 11/03/2016
2. Whiffin N, Hosking FJ, Farrington SM, Palles C, Dobbins SE, Zgaga L, Lloyd A, Kinnersley B, Gorman M, Tenesa A (2014) Identification of susceptibility loci for colorectal cancer in a genome-wide meta-analysis. Hum Mol Genet 23(17):4729–4737
3. Dunlop MG, Dobbins SE, Farrington SM, Jones AM, Palles C, Whiffin N, Tenesa A, Spain S, Broderick P, Ooi L-Y (2012) Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet 44(7):770–776
4. Munkholm P (2003) The incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 18:1–5. doi:10.1046/j.1365-2036.18.s2.2.x
5. Poulogiannis G, Ichimura K, Hamoudi RA, Luo F, Leung SY, Yuen ST, Harrison DJ, Wyllie AH, Arends MJ (2010) Prognostic relevance of DNA copy number changes in colorectal cancer. J Pathol 220(3):338–347
6. Arends MJ (2013) Pathways of colorectal carcinogenesis. Appl Immunohistochem Mol Morphol 21(2):97–102. doi:10.1097/PAI.0b013e3182849808
7. Ibrahim AE, Arends MJ, Silva A-L, Wyllie AH, Greger L, Ito Y, Vowler SL, Huang TH, Tavaré S, Murrell A (2010) Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression. Gut:gut. 2010.223602
8. The Cancer Genome Atlas Network (326 collaborators). Comprehensive molecular characterization of human colon and rectal cancer (2012). Nature 487 (7407):330–337. doi:http://www.nature.com/nature/journal/v487/n7407/abs/nature11252.html#supplementary-information
9. Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S (2015) The consensus molecular subtypes of colorectal cancer. Nat Med 21(11):1350–1356
10. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61(5):759–767
11. Frayling I, Arends M (2013) Adenomatous Polyposis Coli. In: Maloy S, Hughes K (eds) Brenner’s Encyclopedia of Genetics, vol 1, 2nd edition edn. Academic, San Diego, pp 27–29
12. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW (1997) Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 275(5307):1787–1790. doi:10.1126/science.275.5307.1787
13. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Smits AM, Bos JL (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319(9):525–532
14. Silva A-L, Dawson SN, Arends MJ, Guttula K, Hall N, Cameron EA, Huang TH, Brenton JD, Tavaré S, Bienz M (2014) Boosting Wnt activity during colorectal cancer progression through selective hypermethylation of Wnt signaling antagonists. BMC Cancer 14(1):891
15. Bienz M, Clevers H (2000) Linking colorectal cancer to Wnt signaling. Cell 103(2):311–320
16. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96(4):261–268
17. Meyer LA, Broaddus RR, Lu KH (2009) Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control: J Moffitt Cancer Center 16(1):14–22
18. Poulogiannis G, Frayling IM, Arends MJ (2010) DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome. Histopathology 56(2):167–179
19. Gay LJ, Arends MJ, Mitrou PN, Bowman R, Ibrahim AE, Happerfield L, Luben R, McTaggart A, Ball RY, Rodwell SA (2011) MLH1 promoter methylation, diet, and lifestyle factors in mismatch repair deficient colorectal cancer patients from EPIC-Norfolk. Nutr Cancer: Int J 63(7):1000–1010. doi:10.1080/01635581.2011.596987
20. Ibrahim AE, Arends MJ (2012) Molecular typing of colorectal cancer: applications in diagnosis and treatment. Diagn Histopathol 18(2):70–80
21. Tomlinson IP, Novelli M, Bodmer W (1996) The mutation rate and cancer. Proc Natl Acad Sci 93(25):14800–14803
22. Toft NJ, Winton DJ, Kelly J, Howard LA, Dekker M, te Riele H, Arends MJ, Wyllie AH, Margison GP, Clarke AR (1999) Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine. Proc Natl Acad Sci 96(7):3911–3915. doi:10.1073/pnas.96.7.3911
23. Toft NJ, Curtis LJ, Sansom OJ, Leitch AL, Wyllie AH, te Riele H, Arends MJ, Clarke AR (2002) Heterozygosity for p53 promotes microsatellite instability and tumorigenesis on a Msh2 deficient background. Oncogene 21(41):6299–6306
24. Arends M, Ibrahim M, Happerfield L, Frayling I, Miller K (2008) Interpretation of immunohistochemical analysis of mismatch repair (MMR) protein expression in tissue sections for investigation of suspected Lynch/Hereditary Non-Polyposis Colorectal Cancer (HNPCC) syndrome. UK NEQAS ICC & ISH Recommendations 1
25. Arends M, Frayling I, Happerfield L, Ibrahim M (2010) HNPCC/Lynch syndrome module: report of the immunohistochemical analysis of mismatch repair (MMR) protein expression. UK NEQAS ICC & ISH Recommendations 8
26. Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, Church JM, Dominitz JA, Johnson DA, Kaltenbach T, Levin TR, Lieberman DA, Robertson DJ, Syngal S, Rex DK (2014) Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US multi-society task force on colorectal cancer. Gastroenterology 147(2):502–526. doi:10.1053/j.gastro.2014.04.001
27. Domingo E, Niessen RC, Oliveira C, Alhopuro P, Moutinho C, Espín E, Armengol M, Sijmons RH, Kleibeuker JH, Seruca R (2005) BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene 24(24):3995–3998
28. Kawaguchi M, Yanokura M, Banno K, Kobayashi Y, Kuwabara Y, Kobayashi M, Nomura H, Hirasawa A, Susumu N, Aoki D (2009) Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patients with sporadic endometrial cancer. Int J Oncol 34(6):1541–1547
29. Naguib A, Mitrou PN, Gay LJ, Cooke JC, Luben RN, Ball RY, McTaggart A, Arends MJ, Rodwell SA (2010) Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study. BMC Cancer 10:99. doi:10.1186/1471-2407-10-99
30. Naguib A, Cooke JC, Happerfield L, Kerr L, Gay LJ, Luben RN, Ball RY, Mitrou PN, McTaggart A, Arends MJ (2011) Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study: associations with clinicopathological and dietary factors. BMC Cancer 11:123. doi:10.1186/1471-2407-11-123
31. Metcalf AM, Spurdle AB (2013) Endometrial tumour BRAF mutations and MLH1 promoter methylation as predictors of germline mismatch repair gene mutation status: a literature review. Familial Cancer 13(1):1–12. doi:10.1007/s10689-013-9671-6
32. Berg M, Hagland HR, Søreide K (2014) Comparison of CpG island methylator phenotype (CIMP) frequency in colon cancer using different probe-and gene-specific scoring alternatives on recommended multi-gene panels. PLoS One 9(1), e86657
33. Noffsinger AE (2009) Serrated polyps and colorectal cancer: new pathway to malignancy. Annu Rev Pathol Mech Dis 4:343–364
34. Quirke P, Risio M, Lambert R, von Karsa L, Vieth M (2011) Quality assurance in pathology in colorectal cancer screening and diagnosis—European recommendations. Virchows Arch 458(1):1–19
35. Bettington M, Walker N, Clouston A, Brown I, Leggett B, Whitehall V (2013) The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology 62(3):367–386
36. Bettington ML, Walker NI, Rosty C, Brown IS, Clouston AD, McKeone DM, Pearson S-A, Klein K, Leggett BA, Whitehall VL (2015) A clinicopathological and molecular analysis of 200 traditional serrated adenomas. Mod Pathol 28(3):414–427
37. Rad R, Cadiñanos J, Rad L, Varela I, Strong A, Kriegl L, Constantino-Casas F, Eser S, Hieber M, Seidler B, Price S, Fraga Mario F, Calvanese V, Hoffman G, Ponstingl H, Schneider G, Yusa K, Grove C, Schmid Roland M, Wang W, Vassiliou G, Kirchner T, McDermott U, Liu P, Saur D, Bradley A (2013) A genetic progression model of BrafV600E-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell 24(1):15–29. doi:10.1016/j.ccr.2013.05.014
38. Feng Y, Bommer GT, Zhao J, Green M, Sands E, Zhai Y, Brown K, Burberry A, Cho KR, Fearon ER (2011) Mutant Kras promotes hyperplasia and alters differentiation in the colon epithelium but does not expand the presumptive stem cell pool. Gastroenterology 141(3):1003–1013. doi:10.1053/j.gastro.2011.05.007, e1010
39. Tateyama H, Li W, Takahashi E, Miura Y, Sugiura H, Eimoto T (2002) Apoptosis index and apoptosis-related antigen expression in serrated adenoma of the colorectum: the saw-toothed structure may be related to inhibition of apoptosis. Am J Surg Pathol 26(2):249–256
40. Longacre TA, Fenoglio-Preiser CM (1990) Mixed hyperplastic adenomatous polyps/serrated adenomas: a distinct form of colorectal neoplasia. Am J Surg Pathol 14(6):524–537
41. Chetty R, Bateman AC, Torlakovic E, Wang LM, Gill P, Al-Badri A, Arends M, Biddlestone L, Burroughs S, Carey F (2014) A pathologist’s survey on the reporting of sessile serrated adenomas/polyps. J Clin Pathol 67(5):426–430
42. Torlakovic E, Snover DC (1996) Serrated adenomatous polyposis in humans. Gastroenterology 110(3):748–755. doi:10.1053/gast.1996.v110.pm8608884
43. Felipe De Sousa EM, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LP, de Jong JH, de Boer OJ, van Leersum R, Bijlsma MF (2013) Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 19(5):614–618
44. Church DN, Briggs SE, Palles C, Domingo E, Kearsey SJ, Grimes JM, Gorman M, Martin L, Howarth KM, Hodgson SV (2013) DNA polymerase ɛ and δ exonuclease domain mutations in endometrial cancer. Hum Mol Genet 22(14):2820–2828
45. Briggs S, Tomlinson I (2013) Germline and somatic polymerase ϵ and δ mutations define a new class of hypermutated colorectal and endometrial cancers. J Pathol 230(2):148–153
46. Poulogiannis G, McIntyre RE, Dimitriadi M, Apps JR, Wilson CH, Ichimura K, Luo F, Cantley LC, Wyllie AH, Adams DJ, Arends MJ (2010) PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci U S A 107(34):15145–15150. doi:10.1073/pnas.1009941107
47. Day E, Poulogiannis G, McCaughan F, Mulholland S, Arends MJ, Ibrahim AE, Dear PH (2013) IRS2 is a candidate driver oncogene on 13q34 in colorectal cancer. Int J Exp Pathol 94(3):203–211
48. Budinska E, Popovici V, Tejpar S, D’Ario G, Lapique N, Sikora KO, Di Narzo AF, Yan P, Hodgson JG, Weinrich S (2013) Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol 231(1):63–76
49. Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V, Snel MH, Chresta CM, Rosenberg R, Nitsche U, Macarulla T, Capella G, Salazar R, Orphanides G, Wessels LFA, Bernards R, Simon IM (2014) Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer 134(3):552–562. doi:10.1002/ijc.28387
50. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LCG, Lannon WA, Grotzinger C, Del Rio M (2013) A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 19(5):619–625
51. Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi M-C, Schiappa R, Guenot D, Ayadi M, Kirzin S, Chazal M, Fléjou J-F, Benchimol D, Berger A, Lagarde A, Pencreach E, Piard F, Elias D, Parc Y, Olschwang S, Milano G, Laurent-Puig P, Boige V (2013) Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med 10(5), e1001453. doi:10.1371/journal.pmed.1001453
52. Schlicker A, Beran G, Chresta CM, McWalter G, Pritchard A, Weston S, Runswick S, Davenport S, Heathcote K, Castro DA, Orphanides G, French T, Wessels LF (2012) Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genet 5(1):1–15. doi:10.1186/1755-8794-5-66
53. Perez Villamil B, Romera Lopez A, Hernandez Prieto S, Lopez Campos G, Calles A, Lopez Asenjo JA, Sanz Ortega J, Fernandez Perez C, Sastre J, Alfonso R, Caldes T, Martin Sanchez F, Diaz Rubio E (2012) Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC Cancer 12(1):1–13. doi:10.1186/1471-2407-12-260
54. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509–2520
55. Xiao Y, Freeman GJ (2015) The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov 5(1):16–18